Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions

American Journal of Respiratory Cell and Molecular Biology

Volumn 51, Issue 4, 2014, Pages 526-535

  Lenz, Anke Gabriele ^a,b   Stoeger, Tobias ^a,b   Cei, Daniele ^a,b,d   Schmidmeir, Martina ^a,b   Semren, Nora ^a,b   Burgstaller, Gerald ^a,b   Lentner, Bernd ^a,b   Eickelberg, Oliver ^a,b,c   Meiners, Silke ^a,b   Schmid, Otmar ^a,b  

^a Institute of lungs Biology and Disease   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Aerosolized drug delivery; Comparison of air liquid interface and submerged cell culture; Inflammation; Lung epithelial cell; Proteasome inhibitor

Indexed keywords

AEROSOL; ANTIINFLAMMATORY AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; IL8 PROTEIN, HUMAN; INTERLEUKIN 8; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; COMPARATIVE STUDY; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; HUMAN; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; KINETICS; LUNG GAS EXCHANGE; METABOLISM; PROMOTER REGION; REPRODUCIBILITY; RESPIRATORY TRACT MUCOSA; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UPREGULATION; VALIDATION STUDY;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFLAMMATORY AGENTS; BLOOD-AIR BARRIER; BORONIC ACIDS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-8; KINETICS; PROMOTER REGIONS, GENETIC; PROTEASOME INHIBITORS; PYRAZINES; REPRODUCIBILITY OF RESULTS; RESPIRATORY MUCOSA; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84907564668     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0479OC     Document Type: Article

References (41)

1. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6:67-74.
2. Dombu CY, Betbeder D. Airway delivery of peptides and proteins using nanoparticles. Biomaterials 2013;34:516-525.
3. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med 2005;18: 137-182.
4. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol 2005;32:281-289.
5. Schleh C, Kreyling WG, Lehr CM. Pulmonary surfactant is indispensable in order to simulate the in vivo situation. Part Fibre Toxicol 2013;10:6.
6. Hein S, Bur M, Kolb T, Muellinger B, Schaefer UF, Lehr CM. The pharmaceutical aerosol deposition device on cell cultures (PADDOCC) in vitro system: design and experimental protocol. Altern Lab Anim 2010;38:285-295.
7. Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res 2003;20: 788-796.
8. Bur M, Rothen-Rutishauser B, Huwer H, Lehr CM. A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. Eur J Pharm Biopharm 2009; 72:350-357.
9. Grainger CI, Greenwell LL, Martin GP, Forbes B. The permeability of large molecular weight solutes following particle delivery to airinterfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm 2009;71:318-324.
10. Cooney DJ, Hickey AJ. Cellular response to the deposition of diesel exhaust particle aerosols onto human lung cells grown at the air-liquid interface by inertial impaction. Toxicol In Vitro 2011;25: 1953-1965.
11. Knebel JW, Ritter D, Aufderheide M. Exposure of human lung cells to native diesel motor exhaust-development of an optimized in vitro test strategy. Toxicol In Vitro 2002;16:185-192.
12. Schreier H, Gagne L, Conary JT, Laurian G. Simulated lung transfection by nebulization of liposome cDNA complexes using a cascade impactor seeded with 2-CFSMEO-cells. J Aerosol Med 1998;11: 1-13.
13. Hinds WC. Aerosol technology. New York: Wiley-Interscience Publications; 1999.
14. Sharma P, Kolawole AO, Wiltshire SM, Frondorf K, Excoffon KJ. Accessibility of the coxsackievirus and adenovirus receptor and its importance in adenovirus gene transduction efficiency. J Gen Virol 2012;93:155-158.
15. Oostingh GJ, Schmittner M, Ehart AK, Tischler U, Duschl A. A highthroughput screening method based on stably transformed human cells was used to determine the immunotoxic effects of fluoranthene and other PAHs. Toxicol In Vitro 2008;22:1301-1310.
16. Aerogen. Aeroneb Pro user manual. 2013 [revised 2013, accessed 2013 26 Apr]. Available from: http://www.aerogen.com.
17. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010;15:243-249.
18. Alwan A, editor. Global status report on noncommunicable diseases 2010: description of the global burden of NCDs, their risk factors and determinants. Geneva: World Health Organization; 2011. p. 176. Available from: http://www.who.int/nmh/publications/ncd-report2010/en/.
19. Fulcher ML, Randell SH. Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods Mol Biol 2013;945:109-121.
20. Paur H-R, Cassee FR, Teeguarden J, Fissan H, Diabate S, Aufderheide M, Kreyling WG, Hanninen O, Kasper G, Riediker M, et al. In-vitro cell exposure studies for the assessment of nanoparticle toxicity in the lung-a dialog between aerosol science and biology. J Aerosol Sci 2011;42:668-692.
21. Blank F, Rothen-Rutishauser B, Gehr P. Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens. Am J Respir Cell Mol Biol 2007;36:669-677.
22. Schurch S, Gehr P, Im-Hof V, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990;80:17-32.
23. Gehr P, Green FH, Geiser M, Im Hof V, Lee MM, Schurch S. Airway surfactant, a primary defense barrier: mechanical and immunological aspects. J Aerosol Med 1996;9:163-181.
24. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2011;363:2233-2247.
25. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61: 158-171.
26. Deuse T, Blankenberg F, Haddad M, Reichenspurner H, Phillips N, Robbins RC, Schrepfer S. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. Am J Respir Cell Mol Biol 2010;43:403-412.
27. Bur M, Huwer H, Muys L, Lehr CM. Drug transport across pulmonary epithelial cell monolayers: Effects of particle size, apical liquid volume, and deposition technique. J Aerosol Med Pulm Drug Deliv 2010;23:119-127.
28. Lenz AG, Karg E, Lentner B, Dittrich V, Brandenberger C, Rothen- Rutishauser B, Schulz H, Ferron GA, Schmid O. A dose-controlled system for air-liquid interface cell exposure and its application to zinc oxide nanoparticles. Part Fibre Toxicol 2009;6:32.
29. Lenz AG, Karg E, Brendel E, Hinze-Heyn H, Maier KL, Eickelberg O, Stoeger T, Schmid O. Inflammatory and oxidative stress responses of an alveolar epithelial cell line to airborne zinc oxide nanoparticles at the air-liquid interface: A comparison with conventional, submerged cell-culture conditions. Biom Res Int 2013;2013:652632.
30. Zamora PO, Gregory RE, Li AP, Brooks AL. An in vitro model for the exposure of lung alveolar epithelial cells to toxic gases. J Environ Pathol Toxicol Oncol 1986;7:159-168.
31. Aufderheide M, Knebel JW, Ritter D. An improved in vitro model for testing the pulmonary toxicity of complex mixtures such as cigarette smoke. Exp Toxicol Pathol 2003;55:51-57.
32. Bitterle E, Karg E, Schroeppel A, Kreyling WG, Tippe A, Ferron GA, Schmid O, Heyder J, Maier KL, Hofer T. Dose-controlled exposure of A549 epithelial cells at the air-liquid interface to airborne ultrafine carbonaceous particles. Chemosphere 2006;65:1784-1790.
33. Savi M, Kalberer M, Lang D, Ryser M, Fierz M, Gaschen A, Ricka J, Geiser M. A novel exposure system for the efficient and controlled deposition of aerosol particles onto cell cultures. Environ Sci Technol 2008;42:5667-5674.
34. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med (Berl) 2003;81:235-245.
35. Meiners S, Ludwig A, Stangl V, Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 2008;28:309-327.
36. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011;5:101-110.
37. Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A California Cancer Consortium trial. Clin Lung Cancer 2011;12:33-37.
38. Mutlu GM, Budinger GR, Wu M, Lam AP, Zirk A, Rivera S, Urich D, Chiarella SE, Go LH, Ghosh AK, et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-beta(1) signalling. Thorax 2012;67:139-146.
39. U.S. Food and Drug Administration. Critical path initiative on "transforming the way fda-regulated products are developed, evaluated, manufactured, and used". U.S. Food and Drug Administration; 2009. Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/UCM186110.pdf.
40. Brandenberger C, Rothen-Rutishauser B, Muhlfeld C, Schmid O, Ferron GA, Maier KL, Gehr P, Lenz AG. Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model. Toxicol Appl Pharmacol 2010; 242:56-65.
41. Brandenberger C, Muhlfeld C, Ali Z, Lenz AG, Schmid O, Parak WJ, Gehr P, Rothen-Rutishauser B. Quantitative evaluation of cellular uptake and trafficking of plain and polyethylene glycol-coated gold nanoparticles. Small 2010;6:1669-1678.